Therapy News and Research

RSS

Mayo Clinic to break ground for cutting edge cancer therapy facility

Mayo Clinic will break ground for a cutting edge cancer therapy facility on December 13 at its hospital campus in Phoenix. Construction begins this month for a massive $182 million facility to house Mayo Clinic's Proton Beam Therapy program - marking a new era in cancer treatment.

12 Dec 2011

Suppressing STARD9 protein could be a novel strategy to fight cancers

Suppressing a newly identified and characterized protein involved in regulating cell division could be a novel strategy to fight certain cancers because it stops the malignant cells from dividing and causes them to die quickly, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

12 Dec 2011

Celgene announces results from azacitidine Phase 1 study on AML

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens.

12 Dec 2011

Onyx receives FDA Standard Review designation for carfilzomib NDA to treat RRMM

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Standard Review designation to the New Drug Application (NDA) for carfilzomib for the potential treatment of patients with relapsed and refractory multiple myeloma.

12 Dec 2011

PCI-32765 produces durable remissions in Phase I/II CLL clinical trial

A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

New data from TetraLogic's TL32711 study on AML presented at 53rd ASH meeting

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the oral presentation of new data on its Smac mimetic drug candidate TL32711 at the 53rd ASH Annual Meeting and Exposition in San Diego.

12 Dec 2011

ACE inhibitors, ARBs have different effects on heart health of dialysis patients

Two seemingly similar blood pressure-lowering drugs have different effects on the heart health of dialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

12 Dec 2011

Gene therapy can reduce painful bleeding episodes in patients with hemophilia B

Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children's Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.

12 Dec 2011

Many postmenopausal women quit breast cancer drugs early because of side effects

Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring? The first study to actually ask the women themselves -- as well as the largest, most scientifically rigorous study to examine the question -- reports 36 percent of women quit early because of the medications' side effects, which are more severe and widespread than previously known.

12 Dec 2011

New gift to create Morsani College of Medicine building at USF Health

The University of South Florida has renamed its medical college the USF Health Morsani College of Medicine in honor of the philanthropic commitment of Frank and Carol Morsani. In total, the Morsanis have given $37 million to USF Health and a total of $43 million to the university.

12 Dec 2011

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

12 Dec 2011

New guidelines for managing latent tuberculosis from CDC

The U.S. Centers for Disease Control and Prevention (CDC) has released new guidelines on treating so-called “latent” tuberculosis (TB) infection in the United States. They suggest the course of the therapy from about 9 months could be shortened to 3 months.

11 Dec 2011

Researchers discover molecular marker for immediate precursors of blood stem cells

A research team led by Nancy Speck, PhD, professor of Cell and Developmental Biology at the Perelman School of Medicine at the University of Pennsylvania, has discovered a molecular marker for the immediate precursors of hematopoietic (blood) stem cells (HSCs) in the developing embryo, which provides much-needed insights for making these cells from engineered precursors.

9 Dec 2011

Panel recommends close monitoring and delay of treatment for localized, low-risk prostate cancer

An independent panel convened this week by the National Institutes of Health has concluded that many men with localized, low-risk prostate cancer should be closely monitored, permitting treatment to be delayed until warranted by disease progression.

9 Dec 2011

Study explains molecular basis for cherubism disease

The Samuel Lunenfeld Research Institute's Drs. Frank Sicheri, Tony Pawson and Sebastian Guettler, in collaboration with Dr. Robert Rottapel at the Ontario Cancer Institute, have uncovered the detailed architecture of a crucial component of Tankyrase, a protein linked to the bone development disorder cherubism and involved in a myriad of cellular processes.

9 Dec 2011

Shorter, effective treatment for latent TB infection

Research, led by Timothy Sterling, M.D., professor of Medicine at Vanderbilt University Medical Center, has led to an important change in CDC recommendations in the regimen for prevention of the centuries-old scourge, tuberculosis (TB).

9 Dec 2011

ZEN bust-enhancing supplements may increase risk of breast cancer

Women who use bust-enhancing dietary supplements containing the mycoestrogen zearalenone (ZEN), a naturally occurring toxin that widely contaminates agricultural products, could be increasing their risk of breast cancer. That is the warning from breast health experts in a paper published online ahead of print publication in the January issue of IJCP, the International Journal of Clinical Practice.

9 Dec 2011

Research roundup: Depression and Medicaid spending; Saving on chronic care costs?: Mental health coverage

The researchers looked at treatment of depression in Medicaid enrollees in Florida from 1996-2006. They found a 29 percent increase in spending "despite decreases in inpatient costs." They attributed much of the increase to the growing use of antipsychotic drugs. They concluded that "spending for Medicaid enrollees with depression increased substantially, with minimal improvements in quality of care".

9 Dec 2011

VDF, CDC and VDC to educate women about gender-specific DVT risks

Deep vein thrombosis (DVT) is a blood clot in the deep veins in the legs. These clots can break loose and travel to the lungs, causing a potentially fatal pulmonary embolism (PE). Even when they don't, they can cause permanent damage to the leg veins that results in long-term pain, swelling, and disability of the leg.

9 Dec 2011

MRI can predict breast cancer prognosis

Quantitative magnetic resonance imaging measures were associated with prognostic tumor markers, demonstrating the potential of magnetic resonance imaging for prediction of disease prognosis and stratification of patients to appropriate therapies, according to preliminary data presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

9 Dec 2011